Conference abstractPublished 5 Dec 2016
The times they are-a-changin: High intelligence diabetes treatment
Universidade Federal Fluminense, Brazil
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Since this masterpiece of Bob Dylan created in 1964, when diabetic end-organ failures like visual blindness and neuropathy were much more common than today, the traditional therapeutic viewpoints have been the rule rather than the exception. The published results of the UKPDS the reduction of HbA1c levels has been the universal, and even more than that, ubiquitous paradigm in clinical guidelines, in older times for macrovascular diabetic complications and in the more recent times for microvascular diabetic complications. This overconfidence in the reliability of âÂ?Â?safeâÂ? HbA1c levels, unfortunately, has increased over the last decades the frequency of severe hypoglycemic episodes, a high speed delivery into the market of unsafe new antidiabetic drugs, forgetting about the endpoints that mostly matter to the diabetic patient survival and quality of life based on each day shorter and biased clinical trials. The purposes of this talk will be to explain for the audience; the concepts of a soft, a hard, and a surrogate outcome in the clinical spectrum of diabetes; and the relevance of highly intelligent strategies for diabetes therapeutics.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalEndocrinology & Metabolic Syndrome
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Jose Mario Franco De Oliveira”
